1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630578160304128 |
|---|---|
| author | Harriet Kluger Nikhil Joshi Marcus Bosenberg Lilach Aizenbud Noah Hornick Esen Sefik Goran Micevic Andrew Daniels Karine Flem-Karlsen Koonam Park Ronan Talty Meaghan McGeary Haris Mirza Holly N Blackburn Julie F Cheung Akiko Iwasaki Richard Flavell |
| author_facet | Harriet Kluger Nikhil Joshi Marcus Bosenberg Lilach Aizenbud Noah Hornick Esen Sefik Goran Micevic Andrew Daniels Karine Flem-Karlsen Koonam Park Ronan Talty Meaghan McGeary Haris Mirza Holly N Blackburn Julie F Cheung Akiko Iwasaki Richard Flavell |
| author_sort | Harriet Kluger |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:09:09Z |
| format | Article |
| id | doaj.art-18f6bffe16e3475ea18d151820853ec1 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:09:09Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-18f6bffe16e3475ea18d151820853ec12023-11-12T05:45:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.10251025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanomaHarriet Kluger0Nikhil Joshi1Marcus Bosenberg2Lilach Aizenbud3Noah Hornick4Esen Sefik5Goran Micevic6Andrew Daniels7Karine Flem-Karlsen8Koonam Park9Ronan Talty10Meaghan McGeary11Haris Mirza12Holly N Blackburn13Julie F Cheung14Akiko Iwasaki15Richard Flavell164Yale Cancer Center, New Haven, CT, USA1Bristol Heart Institute1Yale University, New Haven, CT, USADepartment of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut, USAYale School of Medicine, New Haven, CT, United StatesDepartment of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA1Yale University, New Haven, CT, USA |
| spellingShingle | Harriet Kluger Nikhil Joshi Marcus Bosenberg Lilach Aizenbud Noah Hornick Esen Sefik Goran Micevic Andrew Daniels Karine Flem-Karlsen Koonam Park Ronan Talty Meaghan McGeary Haris Mirza Holly N Blackburn Julie F Cheung Akiko Iwasaki Richard Flavell 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma Journal for ImmunoTherapy of Cancer |
| title | 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma |
| title_full | 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma |
| title_fullStr | 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma |
| title_full_unstemmed | 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma |
| title_short | 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma |
| title_sort | 1025 tumor specific cd8 t cells epigenetically licensed by il 7r are critical for anti tumor immunity in melanoma |
| work_keys_str_mv | AT harrietkluger 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT nikhiljoshi 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT marcusbosenberg 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT lilachaizenbud 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT noahhornick 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT esensefik 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT goranmicevic 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT andrewdaniels 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT karineflemkarlsen 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT koonampark 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT ronantalty 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT meaghanmcgeary 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT harismirza 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT hollynblackburn 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT juliefcheung 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT akikoiwasaki 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma AT richardflavell 1025tumorspecificcd8tcellsepigeneticallylicensedbyil7rarecriticalforantitumorimmunityinmelanoma |